PharmGKB VIP summary for CFTR published

The PharmGKB summary describing CFTR as a pharmacogene has been published by Pharmacogenetics & Genomics. Genetic variants within the CFTR gene are the target of new Cystic Fibrosis therapies and drugs in development. The hope is that patients will be better treated with personalized medicines tailored to the underlying defects within CFTR. The VIP summary details these treatment strategies and clinically important variants within the CFTR gene.

  • Read the article:

PharmGKB summary: very important pharmacogene information for CFTR.

McDonagh EM, Clancy JP, Altman RB, Klein TE.  

Pharmacogenetics & Genomics. 2014 Dec 15. (Epub ahead of print)

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.